Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adalimumab for endothelial function in anti-CCP positive rheumatoid arthritis
ACTRN12611000972921Phase 2Completed
- Sponsor
- A/Prof Stephen Oakley
- Start
- Jan 2013
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in rheumatoid arthritis (RA) comparing Humira plus usual care with Placebo plus usual care (2 arms). Primary endpoint: Endothelial function by EndoPAT. Started Jan 2013; status: completed.
02
Drugs
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on ACTRN12611000972921.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12611000972921.